Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christodoulos Papadopoulos

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
JAMA Surgery|November 18, 2020
The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology|February 24, 2021
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 26, 2021
Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Diabetes & Metabolic Syndrome|April 20, 2020
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|September 9, 2022
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|July 10, 2021
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|January 26, 2021
Sclerostin and cardiovascular disease: any prognostic implications?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Acta Cardiologica|September 19, 2023
Prompting ChatGPT to perform an umbrella reviewEleftherios Teperikidis, Aristi Boulmpou, Christodoulos Papadopoulos
The American Journal of Cardiology|June 1, 2022
Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
JAMA Surgery|November 18, 2020
The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology|February 24, 2021
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 26, 2021
Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Diabetes & Metabolic Syndrome|April 20, 2020
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|September 9, 2022
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Endocrinologia, Diabetes Y Nutricion|July 10, 2021
Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Kardiologia Polska|January 26, 2021
Sclerostin and cardiovascular disease: any prognostic implications?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Acta Cardiologica|September 19, 2023
Prompting ChatGPT to perform an umbrella reviewEleftherios Teperikidis, Aristi Boulmpou, Christodoulos Papadopoulos
The American Journal of Cardiology|June 1, 2022
Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Pageof 13